Opdivo® (nivolumab) – New indication
March 4, 2022 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), in combination with platinum-doublet chemotherapy, as neoadjuvant treatment of adult patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer (NSCLC).
Top